Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer

MeSH terms

• Ado-Trastuzumab Emtansine
• Antibodies, Monoclonal / adverse effects
• Antibodies, Monoclonal / pharmacokinetics
• Antibodies, Monoclonal / therapeutic use*
• Antibodies, Monoclonal, Humanized
• Antineoplastic Agents / adverse effects
• Antineoplastic Agents / pharmacokinetics
• Antineoplastic Agents / therapeutic use*
• Breast Neoplasms / drug therapy*
• Breast Neoplasms / enzymology
• Breast Neoplasms / immunology
• Breast Neoplasms / mortality
• Breast Neoplasms / pathology
• Disease-Free Survival
• Female
• Humans
• Immunotoxins / adverse effects
• Immunotoxins / pharmacokinetics
• Immunotoxins / therapeutic use*
• Maytansine / adverse effects
• Maytansine / analogs & derivatives*
• Maytansine / pharmacokinetics
• Maytansine / therapeutic use
• Receptor, ErbB-2 / antagonists & inhibitors*
• Receptor, ErbB-2 / metabolism
• Time Factors
• Trastuzumab
• Treatment Outcome